Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 1/20 | 0.52 |
| ▸ | JAK1 | P23458 | 1/20 | 0.52 |
| ▸ | ITK | Q08881 | 1/20 | 0.52 |
| ▸ | CDK7 | P50613 | 9/20 | 0.50 |
| ▸ | SGK1 | O00141 | 1/20 | 0.50 |
| ▸ | ULK1 | O75385 | 1/20 | 0.50 |
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.49 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.48 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.46 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.46 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.46 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.46 |
| ▸ | KAT6A | Q92794 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1460525 | 0.88 | LRRK2 (0.53) | JAK2JAK1ITKCDK7ULK1 | |
| SCHEMBL1461738 | 0.86 | JAK2 (0.52) | JAK2JAK1CDK7ULK1LRRK2 | |
| SCHEMBL1460604 | 0.84 | MAPT (0.58) | JAK2JAK1ITKCDK7ULK1 | |
| SCHEMBL4007934 | 0.80 | MAPT (0.61) | JAK2CDK7AAK1FGFR1FGFR2 | |
| SCHEMBL4010147 | 0.80 | JAK2 (0.50) | JAK2JAK1CDK7ULK1LRRK2 | |
| SCHEMBL28755523 | 0.80 | CDK7 (0.47) | JAK2JAK1CDK7ULK1LRRK2 | |
| SCHEMBL1460534 | 0.79 | ITK (0.66) | ITKSGK1 | |
| SCHEMBL4011476 | 0.78 | HDAC6 (0.49) | JAK2JAK1CDK7ULK1LRRK2 | |
| SCHEMBL1460742 | 0.76 | AURKA (0.53) | JAK2ITKAAK1MEN1ALDH1A1 | |
| SCHEMBL4006558 | 0.74 | CDK7 (0.50) | JAK2JAK1CDK7ULK1LRRK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1487804-B1 | AMINOINDAZOLE DERIVATIVES AS PROTEIN-KINASE INHIBITORS | AVENTIS PHARMA SA (FR) | 2014-02-26 | — | — | EP | disclosed |
| US-6949579-B2 | Aminoindazole derivatives and intermediates, preparation thereof, and pharmaceutical compositions thereof | AVENTIS PHARMA S.A. (FR) | 2005-09-27 | — | — | US | disclosed |
| EP-1487804-A2 | AMINOINDAZOLE DERIVATIVES AS PROTEIN-KINASE INHIBITORS | Aventis Pharma S.A. (FR) | 2004-12-22 | — | — | EP | disclosed |
| US-20040014802-A1 | Aminoindazole derivatives and intermediates, preparation thereof, and pharmaceutical compositions thereof | AVENTIS PHARMA S.A. (FR) | 2004-01-22 | — | — | US | disclosed |
| WO-2003078403-A2 | DERIVES D’AMINOINDAZOLES COMME INHIBITEURS DE PROTEINE-KINASE | AVENTIS PHARMA S.A. (FR) | 2003-09-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040014802-A1 | Aminoindazole derivatives and intermediates, preparation thereof, and pharmaceutical compositions thereof | CYP2C8, NR0B2, NR2C2 | JAK2 1774/4885JAK1 1592/4885ITK 2145/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.